If you stopped by our table at The Michael J. Fox Foundation for Parkinson's Research PDIQ+You Event in Orlando this past weekend - it was nice to meet you! Our team was on site to answer questions and hear from those living with Parkinson's disease and their families about their experiences. Always an event that reminds us of our mission and drives us forward! #ParkinsonsDisease #Advocacy
BlueRock Therapeutics
生物技术研究
Cambridge，Massachusetts 69,158 位关注者
Striving to transform the treatment of disease by harnessing the power of cell therapy
关于我们
BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications. BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. The company strives to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine. Become a BlueRocker! We are expanding our BlueRock team at all locations. Contact us via LinkedIn or our website to learn about rewarding career opportunities.
- 网站
-
https://www.bluerocktx.com
BlueRock Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Cambridge，Massachusetts
- 类型
- 私人持股
- 创立
- 2016
- 领域
- Stem Cell Therapeutics、Engineered Cell Therapy、Cardiology、Neurology、Immunology、Regenerative Medicine和Cell+Gene
地点
BlueRock Therapeutics员工
动态
-
BlueRockers from our patient advocacy team look forward to seeing you at this year's The Michael J. Fox Foundation for Parkinson's Research PDIQ+You events! The first will be in Orlando, FL on March 15. Come say hi!
Parkinson's IQ + You is coming to a city near you this year! ? Central Florida - March 15 ? Twin Cities - May 17 ? Nashville - September 6 ? Honolulu - October 4 PDIQ is The Michael J. Fox Foundation's free educational event series, aimed to help educate people living with Parkinson's and their loved ones. These in-person events feature sessions on navigating Parkinson's, managing care and learning about research participation. Learn more and register: https://bit.ly/4grBrGk
-
-
The theme of International Women’s Day was #AccelerateAction. Throughout the month we will highlight how our own BlueRockers #AccelerateAction at work and at home. Thanks to Julia and Sam from Corporate Communications!
-
-
Yesterday BlueRockers celebrated #InternationalWomensDay with lunch catered by women-owned businesses and a panel featuring four of our brilliant colleagues, Divya Annamraju ACC (she, her), Rebecca Kauffman Milbury, Katie Beasley, PharmD and Natasha Rathee. They shared their career journeys and personal experiences in STEM and beyond. A powerful tool to connect us and learn from one another. BlueRock’s ERG, RockSOLID, will donate to support local women's organizations: Rosie's Place (Boston), Red Door Family Shelter (Toronto), Henry Street Settlement (NYC). #DEIB #IWD2025 #BlueRockers #STEMCareers
-
-
Congratulations to Maya da Luz, who completed her Co-Op at BlueRock and won a McMaster University Co-Op student of the year award. We are so thrilled for you! #STEMCareers
Megan Johnson’s first co-op will be hard to beat. The third-year Environmental Sciences student left the Co-op Student of the Year Awards ceremony with two standout moments. Megan won the McMaster Science Co-op Student of the Year for Level 3 and was also nominated for the Ontario Education Work-Integrated Learning Co-op Student of the Year Award. Megan spent eight months working at Environment and Climate Change Canada as a Student Policy Analyst. Her most notable contribution was completing a comparison of regulatory approaches to managing industrial chemicals in Canada and other jurisdictions. The findings contributed to a Memorandum to Cabinet on chemical regulations. She also played a key role in improving her team’s hiring process, utilizing social media and her academic network to connect with qualified candidates. Megan’s supervisor, Riya Sharma, refers to her as a “secret weapon” for getting things done. “Megan’s exceptional work ethic, attention to detail, and deep understanding of the legislative and policy frameworks that shape our work proved to be an incredible benefit to our team,” Riya said. Co-op Student of the Year Awards were also presented to Maya da Luz, fourth year Chemical Biology student, for her work term with BlueRock Therapeutics, and to Alexandria Mansfield, fifth year Biochemistry student, for her work term with Princess Margaret Cancer Centre, University Health Network. Kriesha Eyer, third year Biochemistry student, Dinuri Punchihewa, fourth year Biology & Pharmacology student, and Narges Kalani, fifth year Chemical Biology student, were also recognized for honourable mention for their outstanding contributions during their co-op term.
-
-
-
-
-
+3
-
-
The theme of International Women’s Day is #AccelerateAction. Throughout the month we will highlight how our own BlueRockers #AccelerateAction at work and at home.?? ? The first is from Katie (Ophthalmology) and Heather?(Regulatory)! #IWD25
-
-
There is so much progress yet to be made into researching treatments for rare diseases. BlueRock is excited to partner with National Organization for Rare Disorders in 2025 to raise awareness. #RareDiseaseDay
-
-
Today we, along with Bayer, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy being tested in a Phase 1/2a clinical trial for the treatment of primary photoreceptor diseases. Read the full release on bluerocktx.com: https://lnkd.in/eS2NcTXj
-
-
In 2024 we expanded our annual Values Awards to include a new team award. This award honors a project team that has demonstrated each of our values in their ways of working and accomplishments together. The inaugural recipients were the team responsible for submitting our successful Investigational New Drug (IND) application for our investigational induced pluripotent stem cell (iPSC)-derived cell therapy being tested in a Phase 1/2a clinical trial for the treatment of primary photoreceptor diseases. Congrats to the team! #Integrity #Courage #Urgency #Community #BlueRockers
-
-
Nothing says 'BlueRock Valentine's Day' like heart-shaped pizza ??, a shared love of snacks ??, and a strong appreciation for lab ops! ???? #BlueRockers #Community
-